OR WAIT null SECS
VectorY, a Netherlands-based biotechnology company, has been selected as the European winner of MilliporeSigma’s 2021 Advance Biotech Grant Program.
MilliporeSigma announced on May 18, 2021 that VectorY, a Netherlands-based biotechnology company, has been selected as the European winner of its 2021 Advance Biotech Grant Program.
The company was selected for its development of proprietary and partnered programs based on a novel adeno-associated viruses (AAV) platform for the treatment of muscular and neurodegenerative disorders, MilliporeSigma said in a company press release. The grant award will provide VectorY with MilliporeSigma products and consultation in upstream processing, sterile and virus filtration, and process development support for gene therapy manufacturing. The award will also accelerate their candidate development and further expand the upstream activities already initiated with the Emerging Biotech team at MilliporeSigma.
VectorY’s offerings include a pipeline of vectorized antibodies for the treatment of muscular and central nervous system diseases with unmet needs, and next-generation vectors and advanced bioprocess technologies aimed at flexible production and overcoming challenges in delivery and manufacturing for advanced gene therapies.
“Our goal is to support the biotech community in bringing the next generation of therapies to the clinic, faster and more efficiently,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma, in the press release. “VectorY’s work could be instrumental in developing potential new treatments for muscular and neurodegenerative diseases.”
“Winning MilliporeSigma’s Advance Biotech Grant is an incredible honor,” added Anthony Newcombe, chief operating officer of VectorY, in the press release. “The support from MilliporeSigma will help us expedite our technology programs and further production scale solutions for next-generation gene therapy manufacturing.”